Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2155 SEK | -8.30% | -36.71% | -97.84% |
Apr. 22 | Transcript : Xbrane Biopharma AB - Special Call | |
Mar. 18 | Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index | CI |
Sales 2024 * | 372M 34.43M | Sales 2025 * | 785M 72.62M | Capitalization | 330M 30.51M |
---|---|---|---|---|---|
Net income 2024 * | -101M -9.35M | Net income 2025 * | 211M 19.53M | EV / Sales 2024 * | 0.51 x |
Net cash position 2024 * | 138M 12.81M | Net cash position 2025 * | 21.29M 1.97M | EV / Sales 2025 * | 0.39 x |
P/E ratio 2024 * |
-2.16
x | P/E ratio 2025 * |
0.04
x | Employees | 93 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.48% |
Latest transcript on Xbrane Biopharma AB
1 day | -8.30% | ||
1 week | -36.71% | ||
Current month | -28.52% | ||
1 month | -56.55% | ||
3 months | -88.40% | ||
6 months | -98.90% | ||
Current year | -97.84% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 14-12-31 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 21-01-10 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 17-10-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 14-12-31 | |
Director/Board Member | 70 | 14-12-31 | |
Director/Board Member | 53 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 0.2155 | -8.30% | 64,018,490 |
24-04-22 | 0.235 | -33.24% | 198,129,300 |
24-04-19 | 0.352 | -3.30% | 20,968,650 |
24-04-18 | 0.364 | +6.59% | 24,708,150 |
24-04-17 | 0.3415 | +0.29% | 19,843,070 |
Delayed Quote Nasdaq Stockholm, April 23, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.84% | 32.92M | |
+3.13% | 42.11B | |
+48.83% | 40.08B | |
+8.49% | 40B | |
-10.82% | 26.87B | |
+8.26% | 24.58B | |
-23.69% | 18.44B | |
+1.58% | 11.94B | |
+32.83% | 11.66B | |
+6.63% | 11.01B |
- Stock Market
- Equities
- XBRANE Stock